Titan Pharmaceuticals, Inc.

Titan did not report quarterly revenue, EPS, or gross margin figures on the call. Management instead said prior operating results are less relevant because the company has transitioned back from a commercial to a development-stage company. On guidance, Titan said it expects JT-09 proof-of-concept data in the second quarter of 2021, expects to file the nalmefene IND in the first half of 2021, and remains on track to seek the remaining approximately $6.3 million of the NIDA grant after IND acceptance.

Marc Rubin framed the quarter as a strategic reset, saying Titan’s recent restructuring is intended to lower fixed operating costs and restore the company to its core strength as a development-stage biotech. He emphasized two main assets, JT-09 and nalmefene, and described both programs as having meaningful development milestones ahead in the first half of 2021. His tone was constructive and forward-looking, with an emphasis on portfolio focus rather than legacy commercial metrics.

No CFO spoke on the call, and no detailed financial statements were discussed beyond strategic capital and funding updates. Management noted a public offering completed two weeks earlier, said the restructuring is expected to substantially reduce fixed operating costs, and highlighted the NIDA grant structure: approximately $8.7 million over 2 years, with about $6.3 million remaining after IND acceptance. They also said NIDA approved reallocating previously approved funds to support additional nonclinical studies needed for nalmefene.

There was no analyst Q&A segment in the transcript. The most notable management clarifications were that JT-09 is now being explored for chronic pruritus, especially in end-stage kidney disease, and that nalmefene will follow the FDA’s 505(b)(1) pathway because of limited safety data for a long-acting formulation. Management also said FDA advised on the needed nonclinical studies and that both programs are expected to reach key milestones by mid-2021.